Rigel Pharmaceuticals | RIGL - Current Liabilities


Rigel Pharmaceuticals reported $94.4M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Agenus USD 231.82M 17.42M Jun/2026
Amgen USD 25.5B 547M Jun/2026
Anika Therapeutics USD 22.15M 1.18M Jun/2026
Arrowhead Research USD 283.35M 11.87M Jun/2026
AstraZeneca USD 31.55B 1.02B Jun/2026
BioMarin Pharmaceutical USD 1.66B 870.84M Jun/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Celldex Therapeutics USD 61.32M 9.85M Jun/2026
Daiichi Sankyo JPY 765.7B 119.32B Jun/2026
Eli Lilly USD 47.74B 11.11B Jun/2026
Halozyme Therapeutics USD 344.44M 18.77M Jun/2026
Heron Therapeutics USD 92.14M 1.63M Jun/2026
Intrexon USD 23.02M 38K Jun/2024
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
Ligand Pharmaceuticals USD 46.74M 6.07M Jun/2026
MacroGenics USD 108.82M 12.88M Jun/2026
Neurocrine Biosciences USD 874.5M 42.8M Jun/2026
Pfizer USD 32.65B 1.7B Jun/2026
Regeneron Pharmaceuticals USD 5.53B 422.9M Jun/2026
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Ultragenyx Pharmaceutical USD 351M 26M Jun/2026
Veracyte USD 62.74M 6.62M Jun/2026